United Therapeutics Corporation (UTHR)

NMS – Цена в реальном времени. Валюта: USD

581.74

+11.86 (2.08%)

При закрытии: May 12, 2026, 4:00 PM EDT

584.82

+3.08 (0.53%)

После закрытия: May 12, 2026, 7:13 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

United Therapeutics Corporation (UTHR)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

United Therapeutics Corporation (UTHR)

United Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare Conference

United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026

UTHR Q1 Earnings Miss Estimates, Shares Jump on Strong Outlook

United Therapeutics Corporation (UTHR) Q1 2026 Earnings Call Transcript

United Therapeutics (UTHR) Misses Q1 Earnings and Revenue Estimates

United Therapeutics Corporation Reports First Quarter 2026 Financial Results

Ahead of United Therapeutics (UTHR) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Видео

No Data

Пресс-релизы

United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026

United Therapeutics Corporation Reports First Quarter 2026 Financial Results

United Therapeutics Corporation Announces Retirement of Professor Raymond Dwek, C.B.E., F.R.S., From Its Board of Directors

United Therapeutics Corporation Presents New Data Spanning Pulmonary Hypertension Treatment, Lung Donor Expansion, and Xenotransplantation at ISHLT 2026

Search stocks

United Therapeutics Corporation (UTHR)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

United Therapeutics Corporation (UTHR)

United Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare Conference

United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026

UTHR Q1 Earnings Miss Estimates, Shares Jump on Strong Outlook

United Therapeutics Corporation (UTHR) Q1 2026 Earnings Call Transcript

United Therapeutics (UTHR) Misses Q1 Earnings and Revenue Estimates

United Therapeutics Corporation Reports First Quarter 2026 Financial Results

Ahead of United Therapeutics (UTHR) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Видео

No Data

Пресс-релизы

United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026

United Therapeutics Corporation Reports First Quarter 2026 Financial Results

United Therapeutics Corporation Announces Retirement of Professor Raymond Dwek, C.B.E., F.R.S., From Its Board of Directors

United Therapeutics Corporation Presents New Data Spanning Pulmonary Hypertension Treatment, Lung Donor Expansion, and Xenotransplantation at ISHLT 2026